Literature DB >> 18238896

Epitope-specific TCRbeta repertoire diversity imparts no functional advantage on the CD8+ T cell response to cognate viral peptides.

Nicole L La Gruta1, Paul G Thomas, Andrew I Webb, Michelle A Dunstone, Tania Cukalac, Peter C Doherty, Anthony W Purcell, Jamie Rossjohn, Stephen J Turner.   

Abstract

TCR repertoire diversity has been convincingly shown to facilitate responsiveness of CD8+ T cell populations to mutant virus peptides, thereby safeguarding against viral escape. However, the impact of repertoire diversity on the functionality of the CD8+ T cell response to cognate peptide-MHC class I complex (pMHC) recognition remains unclear. Here, we have compared TCRbeta chain repertoires of three influenza A epitope-specific CD8+ T cell responses in C57BL/6 (B6) mice: D(b)NP(366-374), D(b)PA(224-233), and a recently described epitope derived from the +1 reading frame of the influenza viral polymerase B subunit (residues 62-70) (D(b)PB1-F2(62)). Corresponding to the relative antigenicity of the respective pMHCs, and irrespective of the location of prominent residues, the D(b)PA(224)- and D(b)PB1-F2(62)-specific repertoires were similarly diverse, whereas the D(b)NP(366) population was substantially narrower. Importantly, parallel analysis of response magnitude, cytotoxicity, TCR avidity, and cytokine production for the three epitope-specific responses revealed no obvious functional advantage conferred by increased T cell repertoire diversity. Thus, whereas a diverse repertoire may be important for recognition of epitope variants, its effect on the response to cognate pMHC recognition appears minimal.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18238896      PMCID: PMC2538877          DOI: 10.1073/pnas.0711682102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Authors:  C Sedlik; G Dadaglio; M F Saron; E Deriaud; M Rojas; S I Casal; C Leclerc
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR.

Authors:  M K Slifka; J L Whitton
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

3.  Analysis of clonotype distribution and persistence for an influenza virus-specific CD8+ T cell response.

Authors:  Stephen J Turner; Gabriela Diaz; Richard Cross; Peter C Doherty
Journal:  Immunity       Date:  2003-04       Impact factor: 31.745

4.  Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense.

Authors:  Ilhem Messaoudi; Jose A Guevara Patiño; Ruben Dyall; Joël LeMaoult; Janko Nikolich-Zugich
Journal:  Science       Date:  2002-11-29       Impact factor: 47.728

Review 5.  Tracking phenotypically and functionally distinct T cell subsets via T cell repertoire diversity.

Authors:  Katherine Kedzierska; Nicole L La Gruta; John Stambas; Stephen J Turner; Peter C Doherty
Journal:  Mol Immunol       Date:  2007-08-24       Impact factor: 4.407

6.  A novel influenza A virus mitochondrial protein that induces cell death.

Authors:  W Chen; P A Calvo; D Malide; J Gibbs; U Schubert; I Bacik; S Basta; R O'Neill; J Schickli; P Palese; P Henklein; J R Bennink; J W Yewdell
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

7.  Mice deficient in perforin, CD4+ T cells, or CD28-mediated signaling maintain the typical immunodominance hierarchies of CD8+ T-cell responses to influenza virus.

Authors:  Weisan Chen; Jack R Bennink; Phillip A Morton; Jonathan W Yewdell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 8.  The many important facets of T-cell repertoire diversity.

Authors:  Janko Nikolich-Zugich; Mark K Slifka; Ilhem Messaoudi
Journal:  Nat Rev Immunol       Date:  2004-02       Impact factor: 53.106

9.  HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.

Authors:  Souheil-Antoine Younes; Bader Yassine-Diab; Alain R Dumont; Mohamed-Rachid Boulassel; Zvi Grossman; Jean-Pierre Routy; Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

10.  A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition.

Authors:  Whitney A Macdonald; Anthony W Purcell; Nicole A Mifsud; Lauren K Ely; David S Williams; Linus Chang; Jeffrey J Gorman; Craig S Clements; Lars Kjer-Nielsen; David M Koelle; Scott R Burrows; Brian D Tait; Rhonda Holdsworth; Andrew G Brooks; George O Lovrecz; Louis Lu; Jamie Rossjohn; James McCluskey
Journal:  J Exp Med       Date:  2003-08-25       Impact factor: 14.307

View more
  29 in total

1.  Primary CTL response magnitude in mice is determined by the extent of naive T cell recruitment and subsequent clonal expansion.

Authors:  Nicole L La Gruta; William T Rothwell; Tania Cukalac; Natasha G Swan; Sophie A Valkenburg; Katherine Kedzierska; Paul G Thomas; Peter C Doherty; Stephen J Turner
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

2.  Quantifiable predictive features define epitope-specific T cell receptor repertoires.

Authors:  Pradyot Dash; Andrew J Fiore-Gartland; Tomer Hertz; George C Wang; Shalini Sharma; Aisha Souquette; Jeremy Chase Crawford; E Bridie Clemens; Thi H O Nguyen; Katherine Kedzierska; Nicole L La Gruta; Philip Bradley; Paul G Thomas
Journal:  Nature       Date:  2017-06-21       Impact factor: 49.962

3.  Epitope specificity delimits the functional capabilities of vaccine-induced CD8 T cell populations.

Authors:  Brenna J Hill; Patricia A Darrah; Zachary Ende; David R Ambrozak; Kylie M Quinn; Sam Darko; Emma Gostick; Linda Wooldridge; Hugo A van den Berg; Vanessa Venturi; Martin Larsen; Miles P Davenport; Robert A Seder; David A Price; Daniel C Douek
Journal:  J Immunol       Date:  2014-10-27       Impact factor: 5.422

4.  Ecological analysis of antigen-specific CTL repertoires defines the relationship between naive and immune T-cell populations.

Authors:  Paul G Thomas; Andreas Handel; Peter C Doherty; Nicole L La Gruta
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-14       Impact factor: 11.205

5.  Reproducible selection of high avidity CD8+ T-cell clones following secondary acute virus infection.

Authors:  Tania Cukalac; Jesseka Chadderton; Andreas Handel; Peter C Doherty; Stephen J Turner; Paul G Thomas; Nicole L La Gruta
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

6.  A clonotype nomenclature for T cell receptors.

Authors:  Maryam B Yassai; Yuri N Naumov; Elena N Naumova; Jack Gorski
Journal:  Immunogenetics       Date:  2009-07-01       Impact factor: 2.846

7.  PB1-F2 proteins from H5N1 and 20 century pandemic influenza viruses cause immunopathology.

Authors:  Julie L McAuley; Jerry E Chipuk; Kelli L Boyd; Nick Van De Velde; Douglas R Green; Jonathan A McCullers
Journal:  PLoS Pathog       Date:  2010-07-22       Impact factor: 6.823

8.  Accurate structure prediction of peptide-MHC complexes for identifying highly immunogenic antigens.

Authors:  Min-Sun Park; Sung Yong Park; Keith R Miller; Edward J Collins; Ha Youn Lee
Journal:  Mol Immunol       Date:  2013-05-18       Impact factor: 4.407

9.  Structures of the MHC-I molecule BF2*1501 disclose the preferred presentation of an H5N1 virus-derived epitope.

Authors:  Xiaoying Li; Lijie Zhang; Yanjie Liu; Lizhen Ma; Nianzhi Zhang; Chun Xia
Journal:  J Biol Chem       Date:  2020-03-09       Impact factor: 5.157

10.  Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection.

Authors:  David A Price; Tedi E Asher; Nancy A Wilson; Martha C Nason; Jason M Brenchley; Ian S Metzler; Vanessa Venturi; Emma Gostick; Pratip K Chattopadhyay; Mario Roederer; Miles P Davenport; David I Watkins; Daniel C Douek
Journal:  J Exp Med       Date:  2009-04-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.